Stock ARCT ARCTURUS THERAPEUTICS HOLDINGS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Arcturus Therapeutics Holdings Inc.

Equities

ARCT

US03969T1097

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
26.55 USD +1.45% Intraday chart for Arcturus Therapeutics Holdings Inc. +2.19% -15.79%
Mar. 27 Arcturus Therapeutics Holdings Insider Sold Shares Worth $610,574, According to a Recent SEC Filing MT
Mar. 21 Arcturus Therapeutics Holdings Insider Sold Shares Worth $299,839, According to a Recent SEC Filing MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024
BU
Arcturus Therapeutics : Positive Results of Phase III Study of Bivalent Version of Kostaive®, Self-Amplifying mRNA Vaccine Against COVID-19 (Ancestral Strain and Omicron BA.4/5), for Booster Vaccination Conducted in Japan - Form 8-K
PU
Arcturus Therapeutics: Q4 Earnings Snapshot
AQ
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress
BU
Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
BU
Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission, for ARCT-032, for the Treatment of Cystic Fibrosis
AQ
Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis
BU
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024
BU
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
BU
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
PR
CSL and Arcturus Therapeutics ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
AQ
CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
BU
CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
PR
Arcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
BU
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in Adults
AQ
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics’ ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in Adults
BU
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults
PR
Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-032, for the Treatment of Cystic Fibrosis
BU
Arcturus Therapeutics: Q3 Earnings Snapshot
AQ
Arcturus Therapeutics Announces Third Quarter 2023 Financial Update and Pipeline Progress
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ARCT Stock
  4. News Arcturus Therapeutics Holdings Inc.
  5. Press Releases